5 Pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; Pharmaceutical preparations and substances for the treatment of psychiatric diseases and disorders; Pharmaceutical preparations for the treatment and prevention of motion sickness; Pharmaceutical preparations for the treatment and prevention of cravings for opioid substances or opiate substances; Pharmaceutical preparations for the treatment and prevention of nausea; Pharmaceutical preparations for the treatment and prevention of vomiting; Pharmaceutical preparations for the treatment and prevention of substance dependence; Pharmaceutical preparations for the treatment and prevention of anxiety; Pharmaceutical preparations for the treatment and prevention of diseases, disorders, or conditions caused by an over-expression of the neuropeptide known as substance P; Pharmaceutical preparations for the treatment and prevention of diseases, disorders, or conditions caused by overstimulation of the neurokinin-1 (NK-1) receptor; Pharmaceutical preparations for the treatment of pruritus; Pharmaceutical preparations for the treatment of atopic dermatitis; Pharmaceutical preparations for the treatment of pain; Pharmaceutical preparations for the treatment of bipolar disorder; Pharmaceutical preparations for the treatment of schizophrenia; Pharmaceutical preparations for the treatment of bile acid diarrhea; Pharmaceutical preparations for the treatment of tyrosine kinase inhibitor (TKI)-induced diarrhea; Pharmaceutical preparations for the treatment of gastroparesis; Pharmaceutical preparations for the treatment of COVID-19; Pharmaceutical preparations for the treatment of inflammatory lung injury (ILI); Pharmaceutical preparations for the treatment of acute respiratory distress syndrome (ARDS); Pharmaceutical preparations for the treatment of social anxiety disorder; Pharmaceutical preparations for the treatment of performance anxiety; Pharmaceutical preparations for the treatment of public speaking anxiety; Pharmaceutical preparations for the treatment of circadian rhythm disorders; Pharmaceutical preparations for the treatment of jet lag disorder; Pharmaceutical preparations for the treatment of insomnia; Pharmaceutical preparations for the treatment of Delayed Sleep Phase Disorder (DSPD); Pharmaceutical preparations for the treatment of non-24 hour sleep/wake disorder; Pharmaceutical preparations for the treatment of Smith-Magenis Syndome; Pharmaceutical preparations for the treatment of nighttime sleep disturbances in patients with Smith-Magenis Syndrome (SMS); Pharmaceutical preparations for the treatment of major depressive disorder (MDD); Pharmaceutical preparations for the treatment of cancer; Pharmaceutical preparations for the treatment of multiple myeloma; Pharmaceutical preparations for the treatment of Charcot-Marie-Tooth disease; Pharmaceutical preparations for the treatment of hematologic malignancies; Pharmaceutical preparations for treating epidermal problems; Pharmaceutical preparations for treating skin disorders; Pharmaceutical preparations for use in dermatology
Trademark: 98350593
